Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation.

University Hospital Lausanne, Lausanne, Switzerland.

Survival: monthsCountry:Switzerland
Toxiciy Grade:City/State/Province:Lausanne
Treatments:Chemotherapy, RadiationHospital:University Hospital Lausanne
Drugs:Journal:Link
Date:Mar 2005

Description:

Patients: This trial involved 206 patients with glioblastoma. Demographic information on the patients was not reported. The patients were randomly divided into two groups. In addition, all patients were categorized based on the level of methylation of the promoter for the gene MGMT; 46 patients in each group had methylated promoters. MGMT methylation is associated with longer survival for glioblastoma patients.

Treatment: Group B (100 patients) received radiotherapy and one chemotherapeutic agent: temozolomide.

Toxicity: Toxicities were not reported in this study.

Results: The focus of this report was to show any correlation in response to temozolomide and the methylation of the MGMT promoter.

Among patients without a methylated MGMT promoter, the overall survival for Group B(chemotherapy + radiotherapy) was 12.7 months. Among patients with a methylated MGMT promoter, the overall survival for Group B (chemotherapy + radiotherapy) was 21.7 months.

The authors concluded that MGMT methylation was a predictor for long-term survival.

Support: Although several authors disclosed receiving consultants fees, no commercial sponsorship of this study was discussed.

Correspondence: Monika E. Hegi, Ph.D.





Back